Poulos collaborates with management teams to craft and execute intellectual property strategies specific to each stage of a company’s lifecycle, including creation, pre-clinical, clinical, venture investment, M&A/IPO exits, and commercialization. She represents investors in IP diligence matters and company creation, focusing on analyzing IP portfolios and creating solutions that optimize the IP portfolio in order to maximize the return on an investment.
“Sabrina’s IP expertise and background in big molecule biology bring critical value to our emerging company and venture capital clients on the West Coast and nationally as we continue to bolster our Life Sciences platform and become the go-to firm for IP matters,” said Mitchell Bloom, chair of Goodwin’s Life Sciences practice. “As the premier global destination for life sciences innovators and investors, we believe it is imperative to continue to build upon our offering in each of our key geographies. IP capacity is not only a critical part of providing full-service advisory to life sciences clients but also to properly structuring complex financing and collaboration transactions, which continue in high volumes despite global economic uncertainty.”
Poulos joins Goodwin as the firm continues to invest in its capital-meets-innovation platform in California and globally. The firm recently added presence in the technology, life sciences, private equity, real estate, and financial industries. In the past month alone, Goodwin welcomed Karen Ubell to the Digital Currency + Blockchain Technology practice in San Francisco, as well as Alex Jacobs to the Real Estate Industry practice in Los Angeles.
Poulos received her J.D. from the University of San Diego School of Law and her B.S. in Biology from the University of North Carolina at Chapel Hill. She is admitted to practice in California and Texas. She can be reached at firstname.lastname@example.org and (415) 733 6241.
Goodwin’s Life Sciences practice represents leading public and private life sciences companies and investors across their entire life cycles – including financings, capital market transactions, mergers and acquisitions, collaborations and licensing, intellectual property and regulatory matters. Goodwin has been named Life Sciences “Practice Group of the Year” by Law360,“ Biotech Firm of the Year” by U.S. News and World Report - Best Law Firms for five years, and “IP Law Firm of the Year,” “Life Cycle Firm of the Year,” “Corporate Firm of the Year” and “Hatch-Waxman Litigation Firm of the Year” by LMG Life Sciences. Mergermarket has named Goodwin the number one legal advisor for Life Sciences and Healthcare M&A (by deal count) in its Deal Drivers Americas 2019 M&A League Tables. Goodwin is ranked among the top law firms for biotech IPOs issuer representation. Over the last two years, Goodwin advised two dozen biotech companies on IPOs raising an aggregate of $3.1 billion.